阿戈美拉汀,CAS 登记号 138112-76-2,由济南圣和化工有限公司现货供应,可提供纯度 按批次COA提供(不公开发布) 的规格,下游主要用于医药中间体及原料药。支持样品与小批量试用,批量价格请联系我们获取,验收以批次 COA 为准。
医药中间体及原料药
每批随货提供 COA;可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号,一个工作日内回复报价。
本页已列出 阿戈美拉汀 的 CAS 号:138112-76-2,可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布),包装形式为 按订单/批次确认(不公开发布),特殊规格可在询价时说明。
主要涉及医药中间体及原料药。
来信 info@591daili.com 或 WhatsApp 联系,提供产品名称、CAS 号与数量,确认价格与交期后即可安排发货,验收以批次 COA 为准。
Agomelatine · CAS 138112-76-2 · C15H17NO2. UNII 137R1N49AD. Solubility: 7.76e-03 g/L.
| CAS Registry Number | 138112-76-2 |
|---|---|
| PubChem CID | 82148 |
| Molecular formula | C15H17NO2 |
| IUPAC name | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide |
| UNII (FDA) | 137R1N49AD |
| Molecular Weight | 243.30 |
|---|---|
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 243.125928785 |
| Monoisotopic Mass | 243.125928785 |
| Topological Polar Surface Area | 38.3 |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Solubility | 7.76e-03 g/L |
|---|
| GHS notification summary | 1.9% (1 / 54) |
|---|
| GHS notification summary | 1.9% (1 / 54) |
|---|---|
| Reported hazard statements | H315 (22.2%), H319 (20.4%), H335 (16.7%), H400 (92.6%) |
This chemical does not meet GHS hazard criteria for 1.9% (1 of 54) of reports.
H315 (22.2%): Causes skin irritation [Warning Skin corrosion/irritation]
Agomelatine; 138112-76-2; Thymanax; Valdoxan; S20098; S-20098; AGO-178; S 20098; Agomelatina; N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide; AGO178; DTXSID3057642; 137R1N49AD; N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide; DTXCID4031431; agomelatinum
CAS 138112-76-2; molecular formula C15H17NO2; molecular weight — g/mol.
Agomelatine, 138112-76-2, Thymanax, Valdoxan, S20098, S-20098.
1.9% of GHS notifications report no hazard classification (1 of 54).
Solubility: 7.76e-03 g/L.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.